BR112021003295A2 - uso de agonistas de receptor alfa-2-adrenérgico para melhorar a visão - Google Patents

uso de agonistas de receptor alfa-2-adrenérgico para melhorar a visão Download PDF

Info

Publication number
BR112021003295A2
BR112021003295A2 BR112021003295-9A BR112021003295A BR112021003295A2 BR 112021003295 A2 BR112021003295 A2 BR 112021003295A2 BR 112021003295 A BR112021003295 A BR 112021003295A BR 112021003295 A2 BR112021003295 A2 BR 112021003295A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
use according
formula
improvement
Prior art date
Application number
BR112021003295-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Mohammed DIBAS
Daniel W. Gil
Wayne Chen
Miguel Alcantara
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of BR112021003295A2 publication Critical patent/BR112021003295A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021003295-9A 2018-08-21 2019-08-20 uso de agonistas de receptor alfa-2-adrenérgico para melhorar a visão BR112021003295A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21
US62/720,671 2018-08-21
PCT/US2019/047305 WO2020041340A1 (en) 2018-08-21 2019-08-20 The use of alpha-2-adrenergic receptor agonists for improving vision

Publications (1)

Publication Number Publication Date
BR112021003295A2 true BR112021003295A2 (pt) 2021-05-18

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021003295-9A BR112021003295A2 (pt) 2018-08-21 2019-08-20 uso de agonistas de receptor alfa-2-adrenérgico para melhorar a visão

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443125A (zh) * 2020-02-20 2022-12-06 阿勒根公司 α-2-肾上腺素能受体激动剂的药物组合物和其用于改善视力的用途
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US20120277239A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development Inc. Compositions and Methods for Improving Night Vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
EP2978406A1 (en) 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Also Published As

Publication number Publication date
AR115991A1 (es) 2021-03-17
SG11202101730SA (en) 2021-03-30
JP2021534217A (ja) 2021-12-09
WO2020041340A1 (en) 2020-02-27
EP3840750A1 (en) 2021-06-30
US20210205273A1 (en) 2021-07-08
KR20210047323A (ko) 2021-04-29
CL2021000440A1 (es) 2021-09-20
US20220160623A1 (en) 2022-05-26
US20220288031A1 (en) 2022-09-15
CA3110318A1 (en) 2020-02-27
CN112823003A (zh) 2021-05-18
US20240358682A1 (en) 2024-10-31
IL280990A (en) 2021-04-29
PH12021550372A1 (en) 2021-11-29
TW202021584A (zh) 2020-06-16
CO2021003460A2 (es) 2021-04-08
AU2019325486A1 (en) 2021-03-25
MX2021002112A (es) 2021-07-16

Similar Documents

Publication Publication Date Title
Verjee et al. Dry eye disease: early recognition with guidance on management and treatment for primary care family physicians
RU2657514C2 (ru) Офтальмологический состав и способ для облегчения пресбиопии
AU2017311636B2 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
US20240358682A1 (en) Use of alpha-2-adrenergic receptor agonists for improving vision
BRPI0821683B1 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
US20240390330A1 (en) Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes
JP2020509085A (ja) アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法
Yanagi et al. Association between glaucoma eye drops and hyperemia
Beerthuizen et al. Straylight values 1 month after laser in situ keratomileusis and photorefractive keratectomy
US11077053B2 (en) Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20240335425A1 (en) Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision
KR20240021734A (ko) 근시의 치료
HK40053072A (en) The use of alpha-2-adrenergic receptor agonists for improving vision
HK40120042A (zh) 包含阿托品的用於防止或延迟近视发作的组合物和方法

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2847 DE 29-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.